September 15th 2025
The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, peritoneal or fallopian tube cancers.
September 14th 2025
September 13th 2025
September 14th 2025
September 12th 2025
September 11th 2025
September 10th 2025
September 11th 2025
September 10th 2025
September 10th 2025
July 13th 2025